Agents approved to treat mRCC like sunitinib, which is a standard of treatment in the clinic, have been proven significantly effective as a first-line therapy in patients with RCC harboring VHL gene mutation, as they target VHL gene-associated hypoxia and related angiogenesis regulated mainly by VEGF and its receptors (23). This evidence concerns the gene VEGFA and renal cell carcinoma.